Should I Buy PRME? PRME 2026 Analysis

Should You Buy Prime Medicine Inc (PRME) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.480

1 Day change

10.48%

52 Week Range

6.940

Analysis Updated At

2026/03/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Prime Medicine Inc (PRME) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, the financial performance shows declining revenue, and the stock trend analysis predicts further downside in the short term. While insider buying and analyst optimism provide some positive signals, the lack of immediate catalysts and weak proprietary trading signals suggest holding off on investment for now.

Technical Analysis

The technical indicators for PRME are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 47.558, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 3.626, with resistance at 3.781 and support at 3.471.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market, but the implied volatility (129.03) and low IV rank (8.53) suggest limited upside potential in the short term.

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased significantly by 18302.86% over the last month.
Analyst coverage from Oppenheimer highlights the company's potential in the gene editing space, with a price target of $11 and potential for 100%-200% upside within 10-15 months.

Neutral/Negative Catalysts

The financials show a significant revenue drop of -61.61% YoY in Q4
Stock trend analysis predicts a 70% chance of a -6.17% decline in the next month.
Technical indicators are bearish, and there are no immediate proprietary trading signals.

Financial Performance

In Q4 2025, revenue dropped significantly by -61.61% YoY to $838,000. Net income improved slightly to -$46.08 million (up 9.00% YoY), but EPS declined to -0.26, down -18.75% YoY. Gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Oppenheimer initiated coverage with an Outperform rating and an $11 price target, citing Prime Medicine's strong position in the gene editing space and potential for significant market share in its pipeline programs.

7 Analyst Rating

Wall Street analysts forecast PRME stock price to rise

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 3.150

Low

4.25

Averages

6.06

High

Current: 3.150

Low

4.25

Averages

6.06

High

Oppenheimer

Outperform

initiated

$11

AI Analysis

2026-03-12

Reason

Oppenheimer

Price Target

$11

AI Analysis

2026-03-12

initiated

Outperform

Reason

Oppenheimer initiated coverage of Prime Medicine with an Outperform rating and $11 price target.

Oppenheimer

Outperform

initiated

$11

2026-03-12

Reason

Oppenheimer

Price Target

$11

2026-03-12

initiated

Outperform

Reason

As previously reported, Oppenheimer initiated coverage of Prime Medicine with an Outperform rating and $11 price target. The firm says Prime is a key name to own in the gene editing space. The company employs prime editing, the best-in-class gene editing approach, validated via early clinical data and a BMS partnership. Prime's pipeline includes a potentially best-in-class AATD program, wherein even 10% market share yields multi-billion-dollar sales, and key opinion leaders believe gene editing could achieve about 50% market share, Oppenheimer adds. Based on peers' valuation, the firm sees potential for about 100%-200% upside following major catalysts within 10-15 months. Further, Oppenheimer believes Prime's high short interest is unrelated to fundamentals.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRME

Unlock Now

PRME Should I Buy

PRME Should I Buy

Should You Buy Prime Medicine Inc (PRME) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch